YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)
Melanoma
Explore 435 assets in Melanoma →Floatz Rating
CCC51/100
Confidence
Indicative
Sponsor
Eucure (Beijing) Biopharma Co., Ltd
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05031494CT.gov A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) (this asset) | Eucure (Beijing) Biopharma Co., Ltd | P2 | CCC · 51 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mucosal Melanoma | — | P2 | B · 57 |
| Cancer | — | P1/2 | CCC · 52 |
| Pancreatic Ductal Adenocarcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. YH-003 (HUMANIZED AGONISTIC ANTI-CD40 IGG2 MONOCLONAL ANTIBODY) in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/yh-003-humanized-agonistic-anti-cd40-igg2-monoclonal-antibody-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →